Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine add-on therapy for schizophrenia symptoms
IRCT20201119049445N2Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing N-acetylcysteine plus usual treatment with Placebo plus usual treatment (2 arms). Primary endpoints: NUCOG total score, NUCOG domain scores and 7 more. Started Jun 2022; status: completed.
02
Drugs
acetylcysteine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20201119049445N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201119049445N2.